A study was conducted in Nova Scotia to assess the risks associated with aprotinin, which the authors hypothesized is associated with higher risk of adverse outcomes than tranexamic acid, according to MDLinx.
The retrospective study looked at 3,340 patients with cardiac surgery and in-hospital outcomes of postoperative mortality, new acute renal failure and perioperative blood transfusion.
Patients who received aprotinin were more often elderly and female. In-hospital mortality was significantly higher in the aprotinin group compared to the TXA group, up 5 percent. The ICU stay was also significantly increased in the aprotinin group, up 8.3 percent.
More Articles on Anesthesia:
Study: Type of General Anesthesia May Not Affect Risk of Myocardial Infarction
Anesthesiologist Dr. Rebecca Patchin to Serve as Joint Commission Board Chair
Marine Corps Searches for Smaller, More Rugged Anesthesia Machines
The retrospective study looked at 3,340 patients with cardiac surgery and in-hospital outcomes of postoperative mortality, new acute renal failure and perioperative blood transfusion.
Patients who received aprotinin were more often elderly and female. In-hospital mortality was significantly higher in the aprotinin group compared to the TXA group, up 5 percent. The ICU stay was also significantly increased in the aprotinin group, up 8.3 percent.
More Articles on Anesthesia:
Study: Type of General Anesthesia May Not Affect Risk of Myocardial Infarction
Anesthesiologist Dr. Rebecca Patchin to Serve as Joint Commission Board Chair
Marine Corps Searches for Smaller, More Rugged Anesthesia Machines